Sort
4,870 grants matching “glp 1”
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis
$479,708Neil A Fanger · Virtici, Llc · R44 · FY2016 · AI
CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease
$479,682Jan Johansson · Artery Therapeutics, Inc. · R44 · FY2019 · AG
Lipid transport in the intestine
$479,192Judith Storch · Rutgers, The State Univ Of N.J. · R01 · FY2023 · DK
Long term change of GLP-1 insulinotropic effect after GBP surgery
$478,573Blandine B Laferrere · Columbia University Health Sciences · R01 · FY2015 · DK
Long term change of GLP-1 insulinotropic effect after GBP surgery
$478,441Blandine B Laferrere · Columbia University Health Sciences · R01 · FY2016 · DK
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1
$478,280Krishna Kumar · Velum, Inc. · R42 · FY2023 · AG
Project 2: PK/PD requirements for mucolytic therapeutic agents in vitro and in vivo
$478,046Richard C Boucher · Univ Of North Carolina Chapel Hill · P01 · FY2020 · HL
Project 2: PK/PD requirements for mucolytic therapeutic agents in vitro and in vivo
$478,046Richard C Boucher · Univ Of North Carolina Chapel Hill · P01 · FY2018 · HL
GIP receptor: The role of post-activation receptor behavior for the incretin effect
$477,598Timothy E McGraw · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · DK
Evaluation of the entero-insular (incretin) axis in cystic fibrosis
$477,125Andrea Bridget Kelly · Children'S Hosp Of Philadelphia · R01 · FY2012 · DK
Obesity Genes, Energy Regulation in Response to Weight-Loss Diets
$477,042Lu Qi · Harvard School Of Public Health · R01 · FY2014 · DK
Discovery and characterization of a novel natural product for the treatment of both diabetes and obesity
$476,912Dongmin Liu · Virginia Polytechnic Inst And St Univ · R01 · FY2025 · DK
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$476,622Elias Sayour · University Of Florida · R37 · FY2022 · CA
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the
$476,117Anne Kathleen Radcliff · Cubrc, Inc. · R01 · FY2013 · AI
Preclinical development of a selective Orexin-1 receptor antagonist for treatment of cocaine addiction
$476,025Craig Fox · C4x Discovery Ltd · R01 · FY2018 · DA
ApoE4-targeted therapeutics that normalize SirT1
$476,014Varghese John · University Of California Los Angeles · R01 · FY2016 · AG
Animal models to assess efficacy of countermeasures for SM-induced toxicity
$475,791Janet M. Benson · Lovelace Biomedical & Environmental Research Institute · U54 · FY2008 · NS
Mechanisms that Direct Airway Remodeling in Obese Asthma
$475,623Jennifer L. Ingram · Duke University · R01 · FY2018 · HL
Neuroendocrine Integration of Satiety and Food Reward
$474,767Diana L Williams · Florida State University · R01 · FY2020 · DK
The Weight-Independent Effects of Bariatric Surgeries on Islet Cell Function
$474,051Marzieh Salehi · University Of Texas Hlth Science Center · R01 · FY2020 · DK
CENTRAL GLP-1 SYSTEMS IN COUNTER REGULATORY RESPONSES
$473,996Beth Israel Deaconess Medical Center · R01 · FY2001 · DK
Project 2: Regulation, circuitry, and function of non-aversive and aversive PBN satiety systems
$473,891David P Olson · University Of Michigan At Ann Arbor · P01 · FY2022 · DK
Project 2: Regulation, circuitry, and function of non-aversive and aversive PBN satiety systems
$473,891David P Olson · University Of Michigan At Ann Arbor · P01 · FY2020 · DK
Project 2: Regulation, circuitry, and function of non-aversive and aversive PBN satiety systems
$473,891David P Olson · University Of Michigan At Ann Arbor · P01 · FY2023 · DK
Project 2: Regulation, circuitry, and function of non-aversive and aversive PBN satiety systems
$473,891David P Olson · University Of Michigan At Ann Arbor · P01 · FY2021 · DK